Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 33395335.
- Also identified by DOI 10.7326/ACPJ202101190-011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fralick M, Kim SC, Schneeweiss S, et al. <b>Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.</b> BMJ. 2020;370:m2812. 32843476.
Medical subject headings
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2